biostudies-literatureCusatis RTakeda Pharmaceuticals U.S.A.GlaxoSmithKlineAmgenBristol Myers Squibb Co.CareDxActinium PharmaceuticalsNHLBI NIH HHSPharmacyclicsMorphoSysAdaptive BiotechnologiesMerckKiadis PharmaKaryopharm TherapeuticsNovartis Pharmaceuticals CorporationSanofi GenzymeNational Cancer InstituteCytoSen TherapeuticsKyowa KirinSeagenIncyteMedacAccenturePfizerMedical College of WisconsinHealth Resources and Services AdministrationAbbVieOffice of Naval ResearchNational Institute of Allergy and Infectious DiseasesJanssen BiotechMiltenyi BiotecGenentechbluebird bioAstellas Pharma USOmeros CorporationBe The Match FoundationNCI NIH HHSDaiichi Sankyo Co., Ltd.Jazz PharmaceuticalsGileadStemCyte229-250https://www.ebi.ac.uk/biostudies/studies/S-EPMC9839494biostudies-literatureUnknown98(2)For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial based on matched donor availability in adults aged 50-75 with higher risk de novo MDS who were candidates for reduced-intensity conditioning (RIC) alloHCT. The primary analysis showed that those who received alloHCT had a survival benefit, but whether this is at the cost of worse quality of life (QOL) has not been described in detail. English- and Spanish-speaking trial participants completed the Functional Assessment of Cancer Therapy-General (FACT-G), the SF-36, and the EQ-5D, at enrollment, every 6 months until 24 monthAmerican journal of hematologyHealth-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.PMC9839494U24 HL138660U10 HL069294UG1 HL069246U24HL138660U24 CA076518U24CA076518U10HL069294Gregory ALee SJLogan BRSaber WCusatis RFlynn KED'Souza AHamilton BKCutler CSShaw BEMartens MJHorowitz MMNakamura RfalseHealth-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial based on matched donor availability in adults aged 50-75 with higher risk de novo MDS who were candidates for reduced-intensity conditioning (RIC) alloHCT. The primary analysis showed that those who received alloHCT had a survival benefit, but whether this is at the cost of worse quality of life (QOL) has not been described in detail. English- and Spanish-speaking trial participants completed the Functional Assessment of Cancer Therapy-General (FACT-G), the SF-36, and the EQ-5D, at enrollment, every 6 months until 24 month2023-01-01T00:00:00Z2023 Feb2025-04-26T11:47:24.239Z2025-02-19T04:59:40.471ZS-EPMC98394943625140110.1002/ajh.26768